TY - JOUR AU - Zhan, Ping AU - Ji, Ya-Nan AU - Yu, Li-Ke PY - 2013 TI - VEGF is associated with the poor survival of patients with prostate cancer: a meta-analysis JF - Translational Andrology and Urology; Vol 2, No 2 (June 16, 2013): Translational Andrology and Urology Y2 - 2013 KW - N2 - Background: Vascular endothelial growth factor (VEGF) is considered as a prime mediator of angiogenesis, and has been implicated in carcinogenesis and metastasis. Various studies examined the relationship between VEGF overexpression with the clinical outcome in patients with prostate cancer, but yielded conflicting results. Methods: Electronic databases updated to July 2013 were searched to find relevant studies. A meta-analysis was conducted with eligible studies which quantitatively evaluated the relationship between VEGF status and survival of patients with prostate cancer. Survival data were aggregated and quantitatively analyzed. Results: We performed a meta-analysis of 9 studies that evaluated the correlation between VEGF overexpression and survival in patients with prostate cancer. Combined hazard ratios suggested VEGF overexpression had an unfavorable impact on overall survival (OS) [hazard ratio (HR) =1.54, 95% CI (confidence interval): 1.25-1.83], but not disease free survival (DFS) (HR=1.23, 95% CI: 0.99-1.47) in patients with prostate cancer. No significant heterogeneity was observed among all studies. Conclusions: VEGF overexpression indicates a poor prognosis for patients with prostate cancer. UR - https://tau.amegroups.org/article/view/2285